#1 Clinical Trials Search in Europe

Ribociclib

Ribociclib, also known as LEE011, is an investigational drug being studied in clinical trials for the treatment of several types of cancer. This article summarizes key information about ongoing clinical trials evaluating the efficacy and safety of ribociclib in conditions such as breast cancer, liposarcoma, glioblastoma, and other solid tumors.

Table of Contents

What is Ribociclib?

Ribociclib, also known by its brand name Kisqali® or research code LEE011, is a medication used primarily in the treatment of certain types of breast cancer[1]. It belongs to a class of drugs called CDK4/6 inhibitors, which work by blocking specific proteins involved in cell division[2].

How Ribociclib Works

Ribociclib works by inhibiting two important proteins in our cells called CDK4 and CDK6. These proteins play a crucial role in controlling how cells divide and grow. By blocking these proteins, ribociclib can help slow down or stop the growth of cancer cells[3].

The medication specifically targets a pathway in cells known as the Rb-E2F pathway. This pathway is often overactive in cancer cells, causing them to multiply rapidly. By interfering with this pathway, ribociclib can help control the spread of cancer[4].

Conditions Treated with Ribociclib

Ribociclib is primarily used to treat:

  • Breast Cancer: Specifically, it’s used for advanced or metastatic breast cancer that is hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-)[2]. This means the cancer cells have receptors for hormones like estrogen or progesterone, but don’t have too many HER2 proteins.
  • Liposarcoma: Some studies are investigating the use of ribociclib in treating well-differentiated or dedifferentiated liposarcoma, a type of soft tissue cancer[5].
  • Brain Tumors: Research is ongoing to evaluate the effectiveness of ribociclib in treating certain types of brain tumors, including glioblastoma and meningioma[4].

Dosage and Administration

Ribociclib is typically taken orally in the form of tablets. The dosage and schedule can vary depending on the specific condition being treated and individual patient factors. However, some common dosing regimens include:

  • 600 mg once daily for 21 days, followed by 7 days off treatment in 28-day cycles[2].
  • 400 mg or 600 mg once daily for 21 days, followed by 7 days off treatment in 28-day cycles[6].

It’s important to note that ribociclib is often used in combination with other medications, such as hormone therapies like fulvestrant or aromatase inhibitors[2].

Potential Side Effects

Like all medications, ribociclib can cause side effects. Some of the potential side effects include:

  • Decreased white blood cell count (neutropenia)
  • Nausea and vomiting
  • Fatigue
  • Diarrhea
  • Hair loss
  • Liver function abnormalities

Your healthcare team will monitor you closely for these side effects and may adjust your dosage or provide supportive care as needed[7].

Ongoing Research and Future Applications

Researchers are continually studying ribociclib to understand its full potential and explore new applications. Some areas of ongoing research include:

  • Early-stage Breast Cancer: Studies are investigating the use of ribociclib in combination with endocrine therapy for patients with early high-risk HR+HER2- breast cancer[6].
  • Brain Tumors: Researchers are exploring how well ribociclib can penetrate the blood-brain barrier and its effectiveness against certain brain tumors[4].
  • Combination Therapies: Various studies are looking at combining ribociclib with other medications to enhance its effectiveness or expand its use to other types of cancers[8].

As research continues, our understanding of ribociclib and its potential applications in cancer treatment will likely expand, potentially offering new hope for patients with various types of cancer.

Cancer Type Trial Phase Combination Therapy Key Outcomes Measured
Breast Cancer (HR+/HER2-) II, III Endocrine therapy Invasive disease-free survival, Overall survival
Liposarcoma II Single agent Progression-free survival, Response rate
Glioblastoma 0/II Single agent Tumor pharmacokinetics, Safety
Advanced Solid Tumors I, II Various combinations Safety, Pharmacokinetics, Tumor response

FAQ

  • What is ribociclib? Ribociclib is an investigational drug that inhibits CDK4/6, which are proteins involved in cell division. It is being studied as a potential treatment for various types of cancer.
  • What types of cancer is ribociclib being tested for? Clinical trials are evaluating ribociclib for breast cancer, liposarcoma, glioblastoma, meningioma, and other advanced solid tumors.
  • How is ribociclib administered in clinical trials? Ribociclib is typically given orally, with dosages ranging from 400-900 mg per day. Common schedules are 21 days on, 7 days off in 28-day cycles.
  • What are some potential side effects of ribociclib? Common side effects may include low blood cell counts, liver enzyme elevations, and ECG abnormalities. Trials are monitoring patients closely for adverse events.
  • How long do patients typically receive ribociclib in clinical trials? Treatment duration varies, but many trials continue ribociclib until disease progression or unacceptable toxicity occurs. Some studies treat patients for up to 3 years.

Ongoing Clinical Trials on Ribociclib

  • Study on Giredestrant and Fulvestrant with CDK4/6 Inhibitor for Patients with ER+ HER2-Negative Advanced Breast Cancer Resistant to Endocrine Therapy

    Recruiting

    1 1 1 1
    Investigated drugs:
    Austria Belgium Finland France Germany Greece +7

  • Study on Ribociclib and Drug Combination for Patients with Advanced HER2-Negative, Hormone Receptor Positive Breast Cancer

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Germany

  • Study Comparing Trastuzumab Deruxtecan with Standard Treatment for Patients with HER2-positive Breast Cancer

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Norway Sweden

  • Study of Capivasertib with CDK4/6 Inhibitors and Fulvestrant for Patients with Advanced HR+/HER2- Breast Cancer

    Recruiting

    1 1 1 1
    Investigated drugs:
    Belgium Denmark France Germany Italy Poland +2

  • Study of Tersolisib and a drug combination for adults with advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation

    Not yet recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium France Germany Greece Italy Spain

  • A study to evaluate if silymarin prevents liver damage caused by ribociclib in patients with hormone receptor positive, HER2-negative breast cancer

    Not yet recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Italy

  • Exercise Program Study for Early Breast Cancer Patients Taking Aromatase Inhibitors With or Without CDK4/6 Inhibitors to Improve Quality of Life

    Not yet recruiting

    1 1 1 1
    Investigated drugs:
    Spain

  • Study to Examine Distribution of Aromatase Inhibitor and Ribociclib in ER+ HER2- Early Breast Cancer in Postmenopausal Women Scheduled for Surgery

    Not yet recruiting

    1 1 1 1
    Investigated drugs:
    The Netherlands

  • Long-term safety study of ribociclib with letrozole, tamoxifen, or goserelin acetate in patients with HR-positive, HER2-negative advanced or metastatic breast cancer

    Not recruiting

    1 1 1 1
    Investigated drugs:
    Greece Italy Poland Portugal Spain

  • Study of PF-07220060 and Letrozole for Adults with HR-Positive, HER2-Negative Advanced Breast Cancer Without Prior Treatment

    Not recruiting

    1 1 1 1
    Investigated drugs:
    Belgium Bulgaria Czechia Denmark Finland France +10

Glossary

  • CDK4/6: Cyclin-dependent kinases 4 and 6, proteins involved in regulating cell division that are targeted by ribociclib
  • Hormone receptor-positive (HR+): Cancer cells that have receptors for estrogen or progesterone, making them potentially responsive to hormone therapies
  • HER2-negative (HER2-): Cancer cells that do not have high levels of the HER2 protein, which promotes cell growth
  • Liposarcoma: A rare type of cancer that develops in fat cells in soft tissues
  • Glioblastoma: An aggressive type of cancer that occurs in the brain or spinal cord
  • Meningioma: A tumor that forms on membranes covering the brain and spinal cord
  • RECIST: Response Evaluation Criteria in Solid Tumors, a standard way to measure how well a cancer patient responds to treatment
  • Progression-free survival (PFS): The length of time during and after treatment that a patient lives without the cancer progressing
  • Overall survival (OS): The length of time from the start of treatment until death from any cause
  • Adverse event (AE): Any unfavorable and unintended sign, symptom, or disease associated with the use of a medical treatment

References

  1. https://clinicaltrials.gov/study/NCT02754011
  2. https://clinicaltrials.eu/trial/study-on-the-safety-and-antitumor-activity-of-arv-471-and-ribociclib-in-adults-with-er-advanced-or-metastatic-breast-cancer/
  3. https://clinicaltrials.gov/study/NCT02345824
  4. https://clinicaltrials.gov/study/NCT02933736
  5. https://clinicaltrials.gov/study/NCT02571829
  6. https://clinicaltrials.gov/study/NCT06587789
  7. https://clinicaltrials.gov/study/NCT05625087
  8. https://clinicaltrials.gov/study/NCT03090165